Company profile: CRISPR Therapeutics
1.1 - Company Overview
Company description
- Provider of a proprietary CRISPR/Cas9 gene-editing platform and therapies to treat serious diseases, including CASGEVY™ (exagamglogene autotemcel), approved in some countries for sickle cell disease and transfusion-dependent beta thalassemia; CTX112, an investigational allogeneic CD19 CAR T therapy; and ex vivo and in vivo gene-editing and cell therapy approaches using viral and non-viral delivery.
Products and services
- CASGEVY™ (exagamglogene autotemcel): A regulatory-approved CRISPR/Cas9 gene-edited therapy that precisely modifies genomic DNA via Cas9 enzyme and guide RNA to treat sickle cell disease and transfusion-dependent beta thalassemia
- CRISPR/Cas9 Gene Editing Platform: A proprietary system enabling precise changes to genomic DNA by cutting and correcting target regions using the Cas9 enzyme and guide RNA to treat serious diseases
- In Vivo Gene Editing: A modular approach delivering gene-editing components directly into the body to treat diseases, utilizing both non-viral and viral delivery methods for precise DNA modification
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CRISPR Therapeutics
American Gene Technologies
HQ: United States
Website
- Description: Provider of gene therapy solutions for infectious diseases, cancers, and inherited disorders. Offerings include AGT103-T, an autologous genetically modified cell product to repair HIV-related immune damage and enable natural control of replication; a PKU gene therapy expected to enter trials in 2025; an immuno-oncology program activating γδ T cells to destroy solid tumors; and a proprietary gene-delivery platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full American Gene Technologies company profile →
Genenta
HQ: Italy
Website
- Description: Provider of gene transfer therapy for cancer, including Temferon, a lentiviral hematopoietic stem progenitor cell immunotherapy enabling controlled, targeted interferon-α expression within tumors to generate immune responses to TEMs-positive cancers. Offers a proprietary cell-based platform using hematopoietic stem cells to deliver therapeutic payloads in the tumor microenvironment for durable, safe treatment of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genenta company profile →
NanoOnc
HQ: United States
Website
- Description: Provider of proprietary offerings, currently expanding operations in Madison, Wisconsin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoOnc company profile →
Kriya Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for ophthalmology, neurology, and metabolic diseases, including KRIYA-825 for geographic atrophy (inhibiting C3/C5; one-time suprachoroidal), KRIYA-586 for thyroid eye disease (blocking IGF1 receptor), KRIYA-839 for diabetes (insulin and glucokinase), KRIYA-497 for NASH (FGF21), and KRIYA-748 and KRIYA-382 for trigeminal neuralgia and focal epilepsy via chemogenetically gated ion channels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kriya Therapeutics company profile →
AavantiBio
HQ: United States
Website
- Description: Provider of gene transfer and gene editing therapies to treat genetic diseases; a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AavantiBio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CRISPR Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CRISPR Therapeutics
2.2 - Growth funds investing in similar companies to CRISPR Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CRISPR Therapeutics
4.2 - Public trading comparable groups for CRISPR Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →